Profile Response Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile KIT exon9
Therapy Imatinib
Indication/Tumor Type gastrointestinal stromal tumor
Response Type sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
KIT exon9 gastrointestinal stromal tumor sensitive Imatinib Case Reports/Case Series Actionable In a Phase III trial (CALGB 150105), Gleevec (imatinib) treatment resulted in a higher objective response rate at a dose of 800mg (n=18) compared to 400mg (n=14) (67% vs 17%, p=0.02) in patients with advanced gastrointestinal stromal tumor harboring KIT exon 9 mutations (PMID: 18955451). 18955451
KIT exon9 gastrointestinal stromal tumor sensitive Imatinib Guideline Actionable Gleevec (imatinib) is included in guidelines for patients with gastrointestinal stromal tumor (GIST) harboring KIT exon 9 mutations (NCCN.org). detail...
KIT exon9 gastrointestinal stromal tumor sensitive Imatinib Guideline Actionable Gleevec (imatinib) is included in guidelines for gastrointestinal stromal tumor (GIST) patients harboring sensitizing mutations, such as KIT exon 9 mutations, as adjuvant therapy for patients with localized disease and as first-line therapy for patients with locally advanced, unresectable, or metastatic disease (PMID: 34560242; ESMO.org). 34560242 detail...
KIT exon9 gastrointestinal stromal tumor sensitive Imatinib Clinical Study - Meta-analysis Actionable In a meta-analysis of two phase III trials (MetaGIST), high-dose Gleevec (imatinib) treatment in patients with gastrointestinal stromal tumors harboring KIT exon 9 mutations resulted in a similar overall survival (p=0.15) but an increased progression-free survival (HR=0.58, p=0.017) and increased best overall response rate (47% vs 21%, p=0.0037) compared to low-dose Gleevec (imatinib) treatment (PMID: 20124181; NCT00685828, NCT00009906). 20124181
PubMed Id Reference Title Details
NCCN.org Full reference...
ESMO Clinical Practice Guidelines Full reference...
(34560242) Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Full reference...
(18955451) Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. Full reference...
(20124181) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. Full reference...